Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Tamiflu Licensees Prepare Production For Domestic Needs

This article was originally published in PharmAsia News

Executive Summary

Shanghai Pharmaceutical Group and Guangdong-based HEC Group, which received Tamiflu manufacturing authentication from Roche, are stepping up preparation for the drug's production. With an output of 40,000 tablets per day, SPG has completed raw material purchase and storage. Its two subsidiaries Hualian Pharmaceutical and Sunway Biotech will be in charge of formulation and pharmaceutical production, respectively. The group has passed 5,000 boxes of its Tamiflu stock to Shanghai municipal government and received a further order of 10,000 boxes from the government. HEC Group currently relies on its existing drug reserves and is gearing up for production. A local Tamiflu shortage exists due to Roche's restriction on sales and output capacity, which can only meet government's requirements. (Click here for more - Chinese language)

You may also be interested in...



What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Vildagliptin Prices Fall By Over 70% In India Post Patent Expiry

Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla

Medtechs Enter The Decade Of Digital, Consumers and Wellness

For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

UsernamePublicRestriction

Register

SC071598

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel